Vaxcyte, Inc. (NASDAQ:PCVX) COO Jim Wassil Sells 8,000 Shares

Vaxcyte, Inc. (NASDAQ:PCVX) COO Jim Wassil sold 8,000 shares of Vaxcyte stock in a transaction that occurred on Monday, March 3rd. The shares were sold at an average price of $73.27, for a total transaction of $586,160.00. Following the completion of the sale, the chief operating officer now owns 154,931 shares in the company, valued at $11,351,794.37. This trade represents a 4.91 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink.

Jim Wassil also recently made the following trade(s):

• On Monday, February 3rd, Jim Wassil sold 8,000 shares of Vaxcyte stock. The shares were sold at an average price of $86.22, for a total transaction of $689,760.00.
• On Thursday, January 2nd, Jim Wassil sold 8,000 shares of Vaxcyte stock. The stock was sold at an average price of $83.66, for a total transaction of $669,280.00.

Vaxcyte Stock Down 1.3 %

PCVX opened at $72.10 on Tuesday. Vaxcyte, Inc. has a 12-month low of $58.10 and a 12-month high of $121.06. The business has a 50 day moving average of $84.30 and a 200-day moving average of $94.91. The stock has a market cap of $9.28 billion, a price-to-earnings ratio of -15.67 and a beta of 0.98.

Vaxcyte (NASDAQ:PCVX) last announced its quarterly earnings results on Tuesday, February 25th. The company reported ($1.02) earnings per share (EPS) for the quarter, beating the consensus estimate of ($1.16) by $0.14. As a group, analysts expect that Vaxcyte, Inc. will post -4.21 earnings per share for the current year.

Institutional Trading of Vaxcyte

A number of hedge funds have recently modified their holdings of PCVX. Natixis Advisors LLC raised its holdings in Vaxcyte by 61.1% in the 3rd quarter. Natixis Advisors LLC now owns 22,697 shares of the company’s stock valued at $2,594,000 after acquiring an additional 8,606 shares during the period. Diversified Trust Co bought a new position in shares of Vaxcyte during the fourth quarter worth approximately $1,433,000. Lisanti Capital Growth LLC increased its stake in shares of Vaxcyte by 68.1% during the third quarter. Lisanti Capital Growth LLC now owns 32,515 shares of the company’s stock worth $3,715,000 after purchasing an additional 13,175 shares during the period. Curi RMB Capital LLC acquired a new stake in Vaxcyte during the 3rd quarter worth approximately $903,000. Finally, WCM Investment Management LLC boosted its stake in Vaxcyte by 52.6% in the 3rd quarter. WCM Investment Management LLC now owns 140,847 shares of the company’s stock valued at $15,935,000 after purchasing an additional 48,543 shares during the period. Institutional investors and hedge funds own 96.78% of the company’s stock.

Analysts Set New Price Targets

A number of research firms recently issued reports on PCVX. Needham & Company LLC reaffirmed a “buy” rating and issued a $140.00 target price on shares of Vaxcyte in a research report on Wednesday, February 26th. The Goldman Sachs Group started coverage on Vaxcyte in a research note on Friday, December 20th. They issued a “buy” rating and a $135.00 price target for the company. Cantor Fitzgerald reiterated an “overweight” rating on shares of Vaxcyte in a research note on Wednesday, November 6th. Finally, Guggenheim reissued a “buy” rating and issued a $160.00 target price on shares of Vaxcyte in a research note on Wednesday, February 26th. Nine equities research analysts have rated the stock with a buy rating, According to MarketBeat.com, the company currently has a consensus rating of “Buy” and a consensus target price of $147.50.

Vaxcyte Company Profile

Vaxcyte, Inc, a clinical-stage biotechnology vaccine company, develops novel protein vaccines to prevent or treat bacterial infectious diseases. Its lead vaccine candidate is VAX-24, a 24-valent investigational pneumococcal conjugate vaccine for the prevention of invasive pneumococcal disease. The company also develops VAX-31 to protect against emerging strains and to help address antibiotic resistance; VAX-A1, a novel conjugate vaccine candidate to prevent disease caused by Group A Streptococcus; VAX-PG, a novel protein vaccine candidate targeting keystone pathogen responsible for periodontitis; and VAX-GI to prevent Shigella, a bacterial illness.